Genelux (NASDAQ:GNLX) PT Lowered to $32.00

Genelux (NASDAQ:GNLX) had its price objective dropped by HC Wainwright from $35.00 to $32.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Genelux’s FY2028 earnings at $0.82 EPS.

Genelux Stock Down 7.4 %

Shares of GNLX stock opened at $4.86 on Tuesday. The stock has a 50 day simple moving average of $7.50 and a 200-day simple moving average of $13.19. Genelux has a 1-year low of $4.86 and a 1-year high of $40.98.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Amalgamated Bank raised its stake in Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after purchasing an additional 770 shares during the last quarter. California State Teachers Retirement System acquired a new position in Genelux in the 2nd quarter valued at $30,000. New York State Common Retirement Fund raised its stake in Genelux by 17.6% in the 4th quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock valued at $91,000 after purchasing an additional 966 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in Genelux in the 1st quarter valued at $32,000. Finally, Legal & General Group Plc raised its stake in Genelux by 535.2% in the 3rd quarter. Legal & General Group Plc now owns 1,696 shares of the company’s stock valued at $41,000 after purchasing an additional 1,429 shares during the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.